Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012-2018.
Clemens EnglerMarco LeoBernhard PfeiferMartin JuchumDi Chen-KoenigKarin PoelzlHans SchoenherrDavid VillJuliana OberdannerEgon EisendleKlaus MiddeldorfBernhard HeindlHannes GaenzerGerald BodeKarl KirchmeyrGuenther LadnerLisa RiegerUrsula KoellenspergerAndrea SchwaigerFlorian StoecklGuenther ZangerlMonika LechleitnerIrmgard DelmarkoWilhelm OberaignerClemens RissbacherHerbert TilgChristoph EbenbichlerPublished in: BMJ open diabetes research & care (2021)
In this long-term, real-world study on prescription changes in the Diabetes Registry Tyrol, we observed significant increase in SGLT-2i, metformin, gliptins and GLP-1a prescriptions. In contrast prescriptions for sulfonylureas declined significantly. Changes were consistent over the years 2012-2018. Changes in prescription patterns occurred even before the publication of international and national guidelines. Thus, physicians change their prescription practice not only based on published guidelines, but even earlier on publication of cardiovascular outcome trials.